Market Overview

Merck Shares Higher Following Bristol-Myers' Phase 3 Disappointment

Share:
Related BMY
The Most Notable Abstracts Released Ahead Of ASCO 2017
Citi Prefers These 4 Stocks Over Pfizer On Bottom-Line Concerns
Related MRK
Zymeworks: Early But Compelling Data, Large Biopharma Partners And A Potential June Catalyst
Sympathy Moves, Explained: Unsympathetic Earnings Season Continues As Nvidia, Advanced Micro Devices Diverge

Shares of Bristol-Myers Squibb (NYSE: BMY) fall 7.15% following Q4 results and management's announcement that the company will continue Phase 1 studies of nivolimab and Yervoy in lung cancer before advancing to Phase 3.

BMO Capital Markets analyst Alex Arfaei's noted that many investors expected a rapid advancement to stage 3 and this news will disappoint. Arfaei added that Bristol-Myer's management comments may be interpreted as a sign of caution.

The analyst reported that this news is “incrementally positive” for Merck & Co. (NYSE: MRK) who is developing a competing therapy in lung cancer, MK- 3475.

Arfaei rates Bristol-Myers as Market Perform with a $56.00 price target, and Merck as Outperform with a $56.00 price target.

Bristol-Myers is currently down 4.75% at $51.39 and shares of Merck are up 0.87% at $52.05.

Latest Ratings for BMY

DateFirmActionFromTo
May 2017BMO CapitalDowngradesMarket PerformUnderperform
Dec 2016JefferiesUpgradesHoldBuy
Oct 2016Hilliard LyonsUpgradesNeutralLong-Term Buy

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

Posted-In: Alex Arfaei BMO Capital MarketsAnalyst Color News Analyst Ratings

 

Related Articles (BMY + MRK)

View Comments and Join the Discussion!